Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate

Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate

ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anadolu psikiyatri dergisi 2017-08, Vol.18 (4), p.1
Hauptverfasser: Ekinci, Ozalp, Gunes, Serkan, Ekinci, Nuran
Format: Artikel
Sprache:eng
Schlagworte:
Attention deficit hyperactivity disorder
Behavior
Child & adolescent psychiatry
Children & youth
Drug dosages
Families & family life
Hallucinations
Hyperactivity
Parents & parenting
Psychosis
Stimulants
Teenagers
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 1
container_title Anadolu psikiyatri dergisi
container_volume 18
creator Ekinci, Ozalp
Gunes, Serkan
Ekinci, Nuran
description ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit Hyperactivity Disorder (ADHD), may be associated with behavioral adverse effects.1 For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. [...]of the case evaluation, modified-release MPH (Medikinet) was firstly licenced in Turkey for ADHD treatment. Since none of his previous treatments were successful, the patient's ADHD medication was switched to modified-release MPH. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
doi_str_mv 10.5455/apd.227212
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1927396191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1927396191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c218t-2537a7204b3b6c0c3685c84d9e005673a87618cf1086fd9de42bb0f02d47d08c3</originalsourceid><addsrcrecordid>eNpdkEtLxDAUhbNQcBhn4y8IuBM65tEm6VIGXzAw4mMd0jxsSjupSQbpv7dSV97FuZuPc-AD4AqjbVVW1a0azZYQTjA5AytMESkYo_gCbFLq0HxU1JjRFehe0qTbkL2GaRrGHIYEVUpBe5Wtgd8-tzDNqVt__IQuhgEeXg9vcLC5nfqxtUdvZhLmAIdgvPPWFNH2ViX7n7kE5071yW7-_hp8PNy_756K_eHxeXe3LzTBIhekolxxgsqGNkwjTZmotChNbRGqGKdKcIaFdhgJ5kxtbEmaBjlETMkNEpquwfXSO8bwdbIpyy6c4nGelLgmnNYM13imbhZKx5BStE6O0Q8qThIj-atQzgrlopD-ACULZ24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1927396191</pqid></control><display><type>article</type><title>Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate</title><source>Alma/SFX Local Collection</source><creator>Ekinci, Ozalp ; Gunes, Serkan ; Ekinci, Nuran</creator><creatorcontrib>Ekinci, Ozalp ; Gunes, Serkan ; Ekinci, Nuran</creatorcontrib><description>ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit Hyperactivity Disorder (ADHD), may be associated with behavioral adverse effects.1 For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. [...]of the case evaluation, modified-release MPH (Medikinet) was firstly licenced in Turkey for ADHD treatment. Since none of his previous treatments were successful, the patient's ADHD medication was switched to modified-release MPH. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.</description><identifier>ISSN: 1302-6631</identifier><identifier>DOI: 10.5455/apd.227212</identifier><language>eng</language><publisher>Sivas: Anatolian Journal of Psychiatry</publisher><subject>Attention deficit hyperactivity disorder ; Behavior ; Child &amp; adolescent psychiatry ; Children &amp; youth ; Drug dosages ; Families &amp; family life ; Hallucinations ; Hyperactivity ; Parents &amp; parenting ; Psychosis ; Stimulants ; Teenagers</subject><ispartof>Anadolu psikiyatri dergisi, 2017-08, Vol.18 (4), p.1</ispartof><rights>Copyright Anatolian Journal of Psychiatry Aug 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ekinci, Ozalp</creatorcontrib><creatorcontrib>Gunes, Serkan</creatorcontrib><creatorcontrib>Ekinci, Nuran</creatorcontrib><title>Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate</title><title>Anadolu psikiyatri dergisi</title><description>ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit Hyperactivity Disorder (ADHD), may be associated with behavioral adverse effects.1 For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. [...]of the case evaluation, modified-release MPH (Medikinet) was firstly licenced in Turkey for ADHD treatment. Since none of his previous treatments were successful, the patient's ADHD medication was switched to modified-release MPH. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.</description><subject>Attention deficit hyperactivity disorder</subject><subject>Behavior</subject><subject>Child &amp; adolescent psychiatry</subject><subject>Children &amp; youth</subject><subject>Drug dosages</subject><subject>Families &amp; family life</subject><subject>Hallucinations</subject><subject>Hyperactivity</subject><subject>Parents &amp; parenting</subject><subject>Psychosis</subject><subject>Stimulants</subject><subject>Teenagers</subject><issn>1302-6631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkEtLxDAUhbNQcBhn4y8IuBM65tEm6VIGXzAw4mMd0jxsSjupSQbpv7dSV97FuZuPc-AD4AqjbVVW1a0azZYQTjA5AytMESkYo_gCbFLq0HxU1JjRFehe0qTbkL2GaRrGHIYEVUpBe5Wtgd8-tzDNqVt__IQuhgEeXg9vcLC5nfqxtUdvZhLmAIdgvPPWFNH2ViX7n7kE5071yW7-_hp8PNy_756K_eHxeXe3LzTBIhekolxxgsqGNkwjTZmotChNbRGqGKdKcIaFdhgJ5kxtbEmaBjlETMkNEpquwfXSO8bwdbIpyy6c4nGelLgmnNYM13imbhZKx5BStE6O0Q8qThIj-atQzgrlopD-ACULZ24</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Ekinci, Ozalp</creator><creator>Gunes, Serkan</creator><creator>Ekinci, Nuran</creator><general>Anatolian Journal of Psychiatry</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20170801</creationdate><title>Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate</title><author>Ekinci, Ozalp ; Gunes, Serkan ; Ekinci, Nuran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c218t-2537a7204b3b6c0c3685c84d9e005673a87618cf1086fd9de42bb0f02d47d08c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Attention deficit hyperactivity disorder</topic><topic>Behavior</topic><topic>Child &amp; adolescent psychiatry</topic><topic>Children &amp; youth</topic><topic>Drug dosages</topic><topic>Families &amp; family life</topic><topic>Hallucinations</topic><topic>Hyperactivity</topic><topic>Parents &amp; parenting</topic><topic>Psychosis</topic><topic>Stimulants</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ekinci, Ozalp</creatorcontrib><creatorcontrib>Gunes, Serkan</creatorcontrib><creatorcontrib>Ekinci, Nuran</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Anadolu psikiyatri dergisi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ekinci, Ozalp</au><au>Gunes, Serkan</au><au>Ekinci, Nuran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate</atitle><jtitle>Anadolu psikiyatri dergisi</jtitle><date>2017-08-01</date><risdate>2017</risdate><volume>18</volume><issue>4</issue><spage>1</spage><pages>1-</pages><issn>1302-6631</issn><abstract>ABSTRACT Methylphenidate (MPH), the firstline medication treatment of attention deficit hyperactivity disorder (ADHD), may be associated with behavioral adverse effects. Metilfenidat, geçiş, psikotik, çocuk INTRODUCTION Methylphenidate (MPH), the firstline medication treatment of Attention Deficit Hyperactivity Disorder (ADHD), may be associated with behavioral adverse effects.1 For ADHD patients with suboptimal symptom control, switching MPH formulations may be helpful. [...]of the case evaluation, modified-release MPH (Medikinet) was firstly licenced in Turkey for ADHD treatment. Since none of his previous treatments were successful, the patient's ADHD medication was switched to modified-release MPH. Pierce D, Katic A, Buckwalter M, Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.</abstract><cop>Sivas</cop><pub>Anatolian Journal of Psychiatry</pub><doi>10.5455/apd.227212</doi></addata></record>
fulltext fulltext
identifier ISSN: 1302-6631
ispartof Anadolu psikiyatri dergisi, 2017-08, Vol.18 (4), p.1
issn 1302-6631
language eng
recordid cdi_proquest_journals_1927396191
source Alma/SFX Local Collection
subjects Attention deficit hyperactivity disorder
Behavior
Child & adolescent psychiatry
Children & youth
Drug dosages
Families & family life
Hallucinations
Hyperactivity
Parents & parenting
Psychosis
Stimulants
Teenagers
title Psychotic symptoms associated with switching from OROS methylphenidate to modified-release methylphenidate
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A32%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychotic%20symptoms%20associated%20with%20switching%20from%20OROS%20methylphenidate%20to%20modified-release%20methylphenidate&rft.jtitle=Anadolu%20psikiyatri%20dergisi&rft.au=Ekinci,%20Ozalp&rft.date=2017-08-01&rft.volume=18&rft.issue=4&rft.spage=1&rft.pages=1-&rft.issn=1302-6631&rft_id=info:doi/10.5455/apd.227212&rft_dat=%3Cproquest_cross%3E1927396191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1927396191&rft_id=info:pmid/&rfr_iscdi=true